Mouse models: Novel in vivo RNAi screen in mice. Transcription: Proteasome power to Def1. Definiens and Advanced Cell Diagnostics Launch Software for Quantitative RNA In Situ Hybridization. Long non-coding RNA HOTAIR, a driver of malignancy, predicts negative prognosis and exhibits oncogenic activity in oesophageal squamous cell carcinoma. Veritas Bio’s RNA Delivery Patent Allowed by EPO. Viral evolution: Fooling the coronavirus proofreading machinery. The ins and outs of hepatitis C virus entry and assembly. Nanoparticles enhance RNA interference. Telomeric RNA-DNA hybrids affect telomere-length dynamics and senescence. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Accelerating the design of biomimetic materials by integrating RNA-seq with proteomics and materials science.
Study Published in Nature Biotechnology Demonstrates Ability of Moderna's Novel Therapeutic Paradigm to Repair and Regenerate Damaged Heart Tissue. Prosensa Initiates First Patient Dosing in Phase I/II trial of PRO053. Company’s fourth exon-skipping compound enters the clinic for the treatment of Duchenne muscular dystrophy LEIDEN, The Netherlands - September 6, 2013 - Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced the dosing of the first patient in its Phase I/II clinical trial of PRO053, an exon-skipping compound for the treatment of Duchenne muscular dystrophy (DMD).
“We are pleased that our fourth exon-skipping compound, PRO053, has advanced into clinical trials.” Giles Campion, Prosensa’s Chief Medical Officer, said. “Bringing new drug candidates, such as PRO053, into the clinic exemplifies how we can leverage our scientific and regulatory expertise gleaned from the experience in advancing the investigational development compound, drisapersen, through the clinic. Notes to editors About Prosensa Holding N.V. Contacts: Prosensa Holding N.V. Frost & Sullivan releases report on global miRNA tools and services market. Frost & Sullivan: Diagnostic and Therapeutic Potential of microRNAs Stimulate Need for More Research Tools.
RNA structure analysis of human spliceosomes reveals a compact 3D arrangement of snRNAs at the catalytic core. The Microprocessor controls the activity of mammalian retrotransposons. Mystaire™Misonix announces the release of MY-PCR Prep workstations. Printed From BioPortfolio.com MY-PCR Prep provides the molecular biology laboratory technician with a “personal cleanroom” for use in the amplification of DNA and RNA. Between amplifications, My-PCR Prep can be irritated with shortwave UV energy to denature potential contaminates and eliminate their ability to be amplified.
The main chamber of MY-PCR Prep is constructed from a continuous piece of polycarbonate to prevent UV light from escaping the chamber during irritation. Operator access is gained through the folding front polycarbonate sash, overlapped to eliminate gaps in the chamber during UV light irritation... Original Article: Mystaire™Misonix announces the release of MY-PCR Prep workstations More From BioPortfolio on "Mystaire™Misonix announces the release of MY-PCR Prep workstations" Advertisement.
Prosensa Holding CEO Discusses Q2 2013 Results - Earnings Call Transcript. Prosensa Holding (RNA) Q2 2013 Earnings Conference Call August 28, 2013 08:00 ET Executives Celia Economides - Director, IR Hans Schikan - CEO Berndt Modig - CFO Analysts James Gordon - JPMorgan Joseph Schwartz - Leerink Swann Chris Marai - Wedbush Jan De Kerpel - KBC Securities John Savin - Edison Investment Research Presentation Operator Good day and welcome to the Prosensa quarter results presentation the conference call.
Celia Economides Thank you operator and thank you all for joining us. Complete Story » Original Article: Prosensa Holding CEO Discusses Q2 2013 Results - Earnings Call Transcript. The miRNA let-7a1 inhibits the expression of insulin-like growth factor 1 receptor (IGF1R) in prostate cancer PC-3 cells. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Identification of a long non-coding RNA-associated RNP complex regulating metastasis at the translational step. Series of RNA biomarkers in blood may help identify who is at risk for committing suicide.
Alnylam obtains additional orphan drug designation for ALN-AT3 from FDA. MiRNA Regulated Networks Identified in Cystic Fibrosis. Alnylam Pharma Gets Addl. Orphan Drug Designation For ALN-AT3 For Hemophilia A. RNA biomarkers in blood may identify people at risk for committing suicide. Automated serial extraction of DNA and RNA from biobanked tissue specimens. RNA Test Aids Bladder Cancer Diagnosis (CME/CE) FDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of hemophilia B. BioStorage Technologies launches INTEGRITY study. New technique in RNA interference cuts time and cost in genetic screens. Tekmira commences Phase I/II study of TKM-PLK1.
Targeting aggressive prostate cancer: How non-coding RNAs fuel cancer growth. Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina Biotech. Study shows enhancer RNA molecules may open new avenues for gene therapy. Genome-wide survey by ChIP-seq reveals YY1 regulation of lincRNAs in skeletal myogenesis. The Yin and Yang of enhancer-like RNAs. Developing microbial cell factories by employing synthetic small RNAs. High Yield RNA Isolation without the Paraffin Removal Step.
Printed From BioPortfolio.com AMSBIO offers a range of kits and reagents for the extraction (isolation) of high quality RNA from FFPE tissues and LCM samples that can be used not only for PCR but also microarray applications. Using AMSBIO ExpressArt® RNA isolation technology it is now possible to achieve high RNA yield and maximum sequence length from FFPE or LCM samples without the paraffin removal step. ExpressArt® RNA technology overcomes traditional limitations placed on research due to limited sample size, RNA degradation and interference from the crosslinking in FFPE samples.
ExpressArt® FFPE RNA-ready isolation and mRNA amplification technology allows researcher to isolate higher quality and quantities of RNA from samples previously unsuitable for gene expression analysis... Original Article: High Yield RNA Isolation without the Paraffin Removal Step More From BioPortfolio on "High Yield RNA Isolation without the Paraffin Removal Step" Advertisement Searches Linking to this Story. Single-cell RNA-Seq profiling of human preimplantation embryos and embryonic stem cells.
Why novel dsRNA molecules in GM food are of little to no concern. Comparative RNA editing in autistic and neurotypical cerebella. Non-coding RNA: Structure and function for lncRNAs. Highly Specific Aptamer Protein Precipitation Kits. Top3β is an RNA topoisomerase that works with fragile X syndrome protein to promote synapse formation. Mutation links intellectual impairment, schizophrenia and autism. Factor receives US patent for RNA reprogramming technology. Moderna Therapeutics names Joseph Bolen president of R&D. Prosensa Awarded EUR 6 million EU FP7 Research Grant. LEIDEN, The Netherlands – August 1, 2013 – Prosensa Holding N.V.
(NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced that it has been awarded a prestigious Framework Programme 7 (FP7) research grant from the European Union to support the ongoing clinical study of the Company’s third novel development candidate, PRO045, for the treatment of Duchenne muscular dystrophy (DMD). The project, titled "Consortium for Products Across Europe in Duchenne Muscular Dystrophy” (SCOPE-DMD) is expected to run for three years. Prosensa is part of a high-quality, pan-European consortium that has been awarded the grant of approximately EUR 6 million to evaluate its exon 45-skipping drug candidate, PRO045, in an innovatively designed clinical proof-of-concept study in boys with DMD. PRO045 is currently in a Phase I/IIa dose-escalating safety study to assess its safety and efficacy. About Prosensa Holding N.V. Fluidigm Enables the Study of miRNA Master Regulators Down to the Single Cell Level.
Dicerna Secures $60 Million in Oversubscribed Series C Financing. Scientists analyze genetic makeup of human and mouse embryos in unprecedented detail. Factor Bioscience Granted First U.S. Patent for RNA-Based Reprogramming Technology. Biotech Industry Veteran Joseph Bolen Joins Moderna Therapeutics to be President of Research and Development. Mirus Announces Transfection Advance: TransIT-X2™ Dynamic Delivery System. Epigenetics, MicroRNAs and Non Coding RNAs in Disease: Market Analysis, Size, Share, Industry Growth, Trends and Forecast Research Report by ResearchMoz.us.
05:20 EDT 31 Jul 2013 | PR Web ResearchMoz.us include new market research report "Epigenetic and MicroRNA Biomarkers 2013 Market Report" to its huge collection of research reports. Browse Full Report - Albany, NY (PRWEB) July 31, 2013 Related Biotechnology, Pharmaceutical and Healthcare News ResearchMoz presents this most up-to-date research on Epigenetic and MicroRNA Biomarkers 2013 Market Report.
The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Epigenetic and MicroRNA Biomarkers Market. The epigenetic and microRNA biomarkers fields are co-evolving and have reached a critical point wherein enough signatures have been identified across various different disease classes, most notably in cancer, that some of these signatures/expression patterns can be validated and deployed for use in the clinic. Table Of Contents Chapter I. About Us: Mirna Therapeutics Announces Important Expansion of microRNA Patent Portfolio.
A small interfering RNA targeting Lnk accelerates bone fracture healing with early neovascularization. Co-crystal structure of a T-box riboswitch stem I domain in complex with its cognate tRNA. Structural biology: RNA exerts self-control. Trovagene Announces Issuance of Broad MicroRNA Patent. Arrowhead Begins Phase 1 Trial of RNAi Therapeutic ARC-520 for Treatment of Chronic Hepatitis B Infection. Researchers explore new treatments for a leading genetic cause of infant deaths. Neuroscience: Along came a long RNA. Riboxx's novel manufacturing process wins European patent.
Translating dosage compensation to trisomy 21. In situ RNA sequencing in preserved cells and tissues. Alnylam rises on 1st human data for subcutaneous RNAi drug. Alnylam Validates Subcutaneous Delivery Technology With Strong Phase I Results. Alnylam Shares Boom on Early Data For Subcutaneous RNA Drug. Alnylam Reports Positive Top-Line Results for ALN-TTRsc, a Subcutaneously Administered RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis.
Three-state mechanism couples ligand and temperature sensing in riboswitches. RNA biophysics: A three-state balancing act. Nanoparticle approach developed to deliver drugs from RNA to silence malfunctioning genes. MiR-22 Plays A Key Role In Both Breast Cancer And Blood Cancer. Researchers gain new molecular-level understanding of the brain's recovery after stroke. New Multichannel Pipette Facilitates High-Throughput RNA Isolation.
Bioportfolio.